Rheumatology Advance Access originally published online on March 9, 2005
Rheumatology 2005 44(6):729-734; doi:10.1093/rheumatology/keh583
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Down-regulation of activating Fc
receptors on monocytes of patients with rheumatoid arthritis upon methotrexate treatment
1 Rheumatology and Clinical Immunology, 2 Immunotherapy Laboratory, Department of Immunology, University Medical Centre Utrecht and 3 Genmab, P.O. Box 85500, 3508 GA Utrecht, The Netherlands.
Correspondence to: J. A. G. van Roon, Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands. E-mail: J.vanRoon{at}azu.nl
Objective. To determine the effect of methotrexate (MTX) on expression levels of activating receptors for IgG (Fc
Rs) on monocytes of rheumatoid arthritis (RA) patients in relation to changes in disease activity.
Methods. The effect of MTX on FcRs on monocytes of RA patients was evaluated ex vivo as well as in vitro. Recently diagnosed, disease-modifying antirheumatic drug (DMARD)-naive RA patients were treated with low-dose MTX. At baseline and 16 weeks after the start of MTX treatment, changes in FcR expression levels on peripheral blood monocytes were evaluated by fluorescence-activated cell sorting analysis and were correlated to changes in disease parameters. To study the direct effects of MTX on monocytes, these cells were isolated from peripheral blood monocytes of healthy controls and cultured with MTX. Other monocyte surface molecules (CD40, CD80, CD86, MHC class II) were also determined to test the specificity of the effect on FcR expression levels.
Results. Eleven out of 15 patients improved clinically (mean disease activity score before 6.2 ± 0.8 vs 4.3 ± 1.7 after). Sixteen weeks after the start of MTX therapy, the expression levels of FcRI and IIa on monocytes were significantly decreased, whereas the decreases in FcRIIIa expression levels on monocytes were less marked. The percentage decrease in FcRI expression correlated with the percentage decrease in CRP and well-being. In vitro MTX selectively decreased FcRI and FcRIIa expression levels of isolated monocytes, in contrast to other surface molecules.
Conclusion. The disease-modifying effect of MTX in the treatment of RA is accompanied by down-regulation of activating FcRI and IIa on monocytes, which could be a direct effect of MTX on monocytes. This down-regulation represents a new mode of action of MTX which should be considered in RA patients, especially during conditions that could give rise to monocyte activation by IgG-containing immune complexes, e.g. during antibody-based therapy of RA.
KEY WORDS: Fc, receptor, Methotrexate, Rheumatoid arthritis, Monocytes/macrophages
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Marois, M. Vaillancourt, S. Marois, S. Proulx, G. Pare, E. Rollet-Labelle, and P. H. Naccache The Ubiquitin Ligase c-Cbl Down-Regulates Fc{gamma}RIIa Activation in Human Neutrophils J. Immunol., February 15, 2009; 182(4): 2374 - 2384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. M. Wessels, T. W. J. Huizinga, and H.-J. Guchelaar Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis Rheumatology, March 1, 2008; 47(3): 249 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kastbom, A. Ahmadi, P. Soderkvist, and T. Skogh The 158V polymorphism of Fc gamma receptor type IIIA in early rheumatoid arthritis: increased susceptibility and severity in male patients (the Swedish TIRA project) Rheumatology, October 1, 2005; 44(10): 1294 - 1298. [Abstract] [Full Text] [PDF]
|
|